Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent GlioblastomaBusiness Wire • 05/25/21
Novocure Gets FDA Approval For Reducing Sample Size For Late-Stage Pivotal LUNAR Lung Cancer StudyBenzinga • 05/18/21
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung CancerBusiness Wire • 05/18/21
NovoCure Limited's (NVCR) CEO Asaf Danziger on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 04/29/21
Novocure Reports First Quarter 2021 Financial Results and Provides Company UpdateBusiness Wire • 04/29/21
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung CancerBusiness Wire • 04/22/21
NovoCure, Synchrony, Twitter, Yum! and More Wednesday Afternoon Analyst Calls24/7 Wall Street • 04/14/21
Independent Monitors Suggest Shorter Timeline for Novocure's Lung Cancer TreatmentThe Motley Fool • 04/13/21
NovoCure surges 65% to all-time high on upbeat review of its lung cancer treatment trial (NVCR)Business Insider • 04/13/21